Clinical Drug Investigation

, Volume 29, Issue 8, pp 491–513 | Cite as

Implications of the European Organisation for Research And Treatment Of Cancer (EORTC) Guidelines on the Use of Granulocyte Colony-Stimulating Factor (G-CSF) for Lymphoma Care

  • Ruth Pettengell
  • Matti Aapro
  • Ercole Brusamolino
  • Dolores Caballero
  • Bertrand Coiffier
  • Michael Pfreundschuh
  • Marek Trneny
  • Jan Walewski
Review Article

Abstract

Febrile neutropenia (FN) is a potentially life-threatening complication of myelosuppressive chemotherapy. The European Organisation for Research and Treatment of Cancer (EORTC) guidelines recommend use of primary granulocyte colony-stimulating factor (G-CSF) prophylaxis if the overall FN risk to a patient is ≥20%, or if a reduction in chemotherapy dose intensity correlates with a poorer outcome. Many of the regimens used for treatment of lymphoma, including R-CHOP (rituximab combined with cyclophos-phamide, doxorubicin, vincristine and prednisolone), are associated with an FN risk of approximately 20% or higher. Individual patient factors that may increase the risk of FN such as advanced age or advanced disease should be taken into account when assessing the need for G-CSF support. Predictive models are being developed to facilitate individual risk assessment. Additional anti-infective prophylaxis may be indicated in some settings. There is now much evidence for the benefits of G-CSF in reducing the incidence of FN and facilitating delivery of chemotherapy, including dose-escalated and dose-dense (interval-reduced) regimens. If given according to guidelines, G-CSF has the potential to reduce FN and related morbidity. Furthermore, by facilitating delivery of planned chemotherapy, use of G-CSF may potentially influence survival in the curative setting. Implementation of the EORTC guidelines will lead to a greater proportion of patients receiving G-CSFs, but the costs involved should be at least partly offset by a reduction in FN and its associated costs, including those of hospitalization.

Notes

Acknowledgements

Financial support for this review was provided by Amgen Europe GmbH. Gardiner-Caldwell Communications (GCC), Macclesfield, UK assisted in the writing of this review. R. Pettengell has served on advisory boards or received honoraria from Amgen, Bayerhealthcare, Chugai and Roche; M. Aapro has received research grants or honoraria from Roche, Sanofi-Aventis, Sandoz and Chugai; M. Pfreundschuh has served on advisory boards for Roche and Eli Lilly; M. Trneny has received honoraria and research grant support from Amgen; J. Walewski has received honoraria for lectures and consultations from Amgen. The other authors have no conflicts of interest that are directly relevant to the content of this review.

References

  1. 1.
    Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 2004 Jan; 100(9): 228–37PubMedCrossRefGoogle Scholar
  2. 2.
    Komroki RS, Lyman GH. The colony-stimulating factors: use to prevent and treat neutropenia and its complications. Expert Opin Biol Ther 2004 Dec; 4(12): 1897–910CrossRefGoogle Scholar
  3. 3.
    Aapro MS, Cameron DA, Pettengell R, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006 Oct; 42(15): 2433–53PubMedCrossRefGoogle Scholar
  4. 4.
    Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006 May; 106(10): 2258–66PubMedCrossRefGoogle Scholar
  5. 5.
    National Comprehensive Cancer Network. Myeloid growth factors. Practice Guidelines in Oncology v. 1.2009 [online]. Available from URL: http://www.nccn.org/ professionals/physician_gls/PDF/myeloid_growth.pdf [Accessed 2009 Jun 2]Google Scholar
  6. 6.
    Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006 Jul; 24(19): 3187–205PubMedCrossRefGoogle Scholar
  7. 7.
    Repetto L, Biganzoli L, Koehne CH, et al. EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer. Eur J Cancer 2003 Nov; 39(16): 2264–72PubMedCrossRefGoogle Scholar
  8. 8.
    Pettengell R, Bosly A, Szucs TD, et al. Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study. Br J Haematol 2009 Mar; 144(5): 677–85PubMedCrossRefGoogle Scholar
  9. 9.
    Lyman GH, Crawford J, Kuderer NM, et al. Final risk prediction model for neutropenic complications in patients receiving cancer chemotherapy. Blood (ASH Annual Meeting Abstracts) 2008; 112(11): 1312Google Scholar
  10. 10.
    Lyman GH, Morrison VA, Dale DC, et al. Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin’s lymphoma receiving CHOP chemotherapy. Leuk Lymphoma 2003 Dec; 44(12): 2069–76PubMedCrossRefGoogle Scholar
  11. 11.
    Lyman GH, Delgado DJ. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediategrade non-Hodgkin lymphoma. Cancer 2003 Dec; 98(11): 2402–9PubMedCrossRefGoogle Scholar
  12. 12.
    Noga SJ, Choksi J, Ding B, et al. Low incidence of neutropenic events in patients with lymphoma receiving first-cycle pegfilgrastim with chemotherapy: results from a prospective community-based study. Clin Lymphoma Myeloma 2007; 7: 413–20PubMedCrossRefGoogle Scholar
  13. 13.
    Armitage JO, Longo DL. Malignancies of lymphoid cells. In: Kaspar DL, Braunwald E, Fauci AS, et al. editors. Harrison’s principles of internal medicine. 16th ed. New York: McGraw-Hill, 2005: 641–55Google Scholar
  14. 14.
    Chrischilles EA, Klepser DG, Brooks JM, et al. Effect of clinical characteristics on neutropenia-related inpatient costs among newly-diagnosed non-Hodgkin’s lymphoma patients during first course chemotherapy. Pharmacotherapy 2005 May; 25(5): 668–75PubMedCrossRefGoogle Scholar
  15. 15.
    Gafter-Gvili A, Fraser A, Paul M, et al. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 2005 Jun; 142(12 Pt 1): 979–95PubMedGoogle Scholar
  16. 16.
    van de Wetering MD, de Witte MA, Kremer LC, et al. Efficacy of oral prophylactic antibiotics in neutropenic afebrile oncology patients: a systematic review of randomised controlled trials. Eur J Cancer 2005 Jul; 41(10): 1372–82PubMedCrossRefGoogle Scholar
  17. 17.
    Leibovici L, Paul M, Cullen M, et al. Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions. Cancer 2006 Oct; 107(8): 1743–51PubMedCrossRefGoogle Scholar
  18. 18.
    Wadhwa PD, Morrison VA. Infectious complications of chronic lymphocytic leukemia. Semin Oncol 2006 Apr; 33(2): 240–9PubMedCrossRefGoogle Scholar
  19. 19.
    Kimby E. Tolerability and safety of rituximab (Mab-Thera). Cancer Treat Rev 2005 Oct; 31(6): 456–73PubMedCrossRefGoogle Scholar
  20. 20.
    Ram R, Ben-Bassat I, Shpilberg O, et al. The late adverse events of rituximab therapy: rare but there! Leuk Lymphoma 2009 Apr 24; 1–13Google Scholar
  21. 21.
    Pettengell R, Gurney H, Radford JA, et al. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin’s lymphoma: a randomized controlled trial. Blood 1992 Sep; 80(6): 1430–6PubMedGoogle Scholar
  22. 22.
    Bertini M, Freilone R, Vitolo U, et al. The treatment of elderly patients with aggressive non-Hodgkin’s lymphomas: feasibility and efficacy of an intensive multidrug regimen. Leuk Lymphoma 1996 Aug; 22(5–6): 483–93PubMedCrossRefGoogle Scholar
  23. 23.
    Zinzani PL, Pavone E, Storti S, et al. Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin’s lymphoma. Blood 1997 Jun; 89(11): 3974–9PubMedGoogle Scholar
  24. 24.
    Burton C, Linch D, Hoskin P, et al. A phase III trial comparing CHOP to PMitCEBO with or without G-CSF in patients aged 60 plus with aggressive non-Hodgkin’s lymphoma. Br J Cancer 2006 Mar; 94(6): 806–13PubMedCrossRefGoogle Scholar
  25. 25.
    Intragumtornchai T, Sutheesuphon J, Sutcharitchan P, et al. A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin’s lymphoma. Leuk Lymphoma 2000 Apr; 37(3–4): 351–60PubMedGoogle Scholar
  26. 26.
    Parekh S, Ratech H, Sparano JA. Human immunodeficiency virus-associated lymphoma. Clin Adv Hematol Oncol 2003 May; 1(5): 295–301PubMedGoogle Scholar
  27. 27.
    Kitay-Cohen Y, Lishner M, Shelef A, et al. Bone marrow involvement, in intensively treated patients with intermediate grade non-Hodgkin’s lymphoma, is a risk factor for granulocytopenia and fever. Leuk Lymphoma 1996 Jan; 20(3–4): 333–6PubMedCrossRefGoogle Scholar
  28. 28.
    Grigg A, Solal-Celigny P, Hoskin P, et al. Open-label, randomized study of pegfilgrastim vs daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin’s lymphoma. Leuk Lymphoma 2003 Sep; 44(9): 1503–8PubMedCrossRefGoogle Scholar
  29. 29.
    Chen-Hardee S, Chrischilles EA, Voelker MD, et al. Population-based assessment of hospitalisations for neutropenia from chemotherapy in older adults with non-Hodgkin’s lymphoma (United States). Cancer Causes Control 2006 Jun; 17(5): 647–54PubMedCrossRefGoogle Scholar
  30. 30.
    Toren A, Nagler R, Nagler A. Involved field radiation post autologous stem cell transplantation in lymphoma patients is associated with major haematological toxicities. Med Oncol 1998 Jul; 15(2): 113–18PubMedCrossRefGoogle Scholar
  31. 31.
    Auner HW, Sill H, Mulabecirovic A, et al. Infectious complications after autologous hematopoietic stem cell transplantation: comparison of patients with acute myeloid leukemia, malignant lymphoma, and multiple myeloma. Ann Hematol 2002 Jul; 81(7): 374–7PubMedCrossRefGoogle Scholar
  32. 32.
    Gisselbrecht C, Haioun C, Lepage E, et al. Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin’s lymphoma: factors influencing chemotherapy administration. Leuk Lymphoma 1997 Apr; 25(3–4): 289–300PubMedGoogle Scholar
  33. 33.
    Ozer H, Armitage JO, Bennett CL, et al. 2000 update of recommendations for the use of haematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 2000 Oct; 18(20): 3558–85PubMedGoogle Scholar
  34. 34.
    Rueda Dominguez A, Márquez A, Gumá J, et al. Treatment of stage I and II Hodgkin’s lymphoma with ABVD chemotherapy: results after 7 years of a prospective study. Ann Oncol 2004 Dec; 15(12): 1798–804PubMedCrossRefGoogle Scholar
  35. 35.
    Gobbi PG, Levis A, Chisesi T, et al. ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin’s lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linformi. J Clin Oncol 2005 Dec; 23(36): 9198–207PubMedCrossRefGoogle Scholar
  36. 36.
    Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N Engl J Med 2003 Jun; 348(24): 2386–95PubMedCrossRefGoogle Scholar
  37. 37.
    Engert A, Bredenfeld H, Döhner H, et al. Pegfilgrastim support for full delivery of BEACOPP-14 chemotherapy for patients with high-risk Hodgkin’s lymphoma: results of a phase II study. Haematologica 2006 Apr; 91(4): 546–9PubMedGoogle Scholar
  38. 38.
    Dunlop DJ, Eatock MM, Paul J, et al. Randomized multicentre trial of filgrastim as an adjunct to combination chemotherapy for Hodgkin’s disease. West of Scotland Lymphoma Group. Clin Oncol (R Coll Radiol) 1998; 10(2): 107–14CrossRefGoogle Scholar
  39. 39.
    Doorduijn JK, van der Holt B, van Imhoff GW, et al. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin’s lymphoma. J Clin Oncol 2003 Aug; 21(16): 3041–50PubMedCrossRefGoogle Scholar
  40. 40.
    Osby E, Hagberg H, Kvaløy S, et al. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood 2003 May; 101(10): 3840–8PubMedCrossRefGoogle Scholar
  41. 41.
    Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005 Mar; 23(9): 1984–92PubMedCrossRefGoogle Scholar
  42. 42.
    Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006 Jul; 24(19): 3121–7PubMedCrossRefGoogle Scholar
  43. 43.
    Nickenig C, Dreyling M, Hoster E, et al. Combined cyclo-phosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group. Cancer 2006 Sep; 107(5): 1014–22PubMedCrossRefGoogle Scholar
  44. 44.
    Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002 Jan; 346(4): 235–42PubMedCrossRefGoogle Scholar
  45. 45.
    Itoh K, Ohtsu T, Fukuda H, et al. Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin’s lymphoma: Japan Clinical Oncology Group Study 9505. Ann Oncol 2002 Sep; 13(9): 1347–55PubMedCrossRefGoogle Scholar
  46. 46.
    Pfreundschuh M, Trümper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004 Aug; 104(3): 634–41PubMedCrossRefGoogle Scholar
  47. 47.
    Sonneveld P, van Putten W, Biesma D, et al. Phase III trial of 2-weekly CHOP with rituximab for aggressive B-cell non-Hodgkin’s lymphoma in elderly patients [abstract]. Blood (ASH Meeting Abstracts) 2006; 108(1): 210Google Scholar
  48. 48.
    Cunningham D, Smith P, Mouncey P, et al. A phase III trial comparing R-CHOP 14 and R-CHOP 21 for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin’s lymphoma [abstract]. J Clin Oncol (Meeting Abstracts) 2009 May; 27(15S): 8506Google Scholar
  49. 49.
    Brusamolino E, Rusconi C, Montalbetti L, et al. Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity. Haematologica 2006 Apr; 91(4): 496–502PubMedGoogle Scholar
  50. 50.
    Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005 Feb; 105(4): 1417–23PubMedCrossRefGoogle Scholar
  51. 51.
    Hagenbeek A, Eghbali H, Monfardini S, et al. Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant non-Hodgkin’s lymphoma. J Clin Oncol 2006 Apr; 24(10): 1590–6PubMedCrossRefGoogle Scholar
  52. 52.
    Mead GM, Sydes MR, Walewski J, et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt’s lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol 2002 Aug; 13(8): 1264–74PubMedCrossRefGoogle Scholar
  53. 53.
    Thomas DA, Faderl S, O’Brien S, et al. Chemo-immunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-like lymphoma or acute lymphoblastic leukemia. Cancer 2006 Apr; 106(7): 1569–80PubMedCrossRefGoogle Scholar
  54. 54.
    Pettengell R, Schwenkglenks M, Leonard R, et al. Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study. Support Care Cancer 2008 Nov; 16(11): 1299–309PubMedCrossRefGoogle Scholar
  55. 55.
    Buske C, Gisselbrecht C, Gribben J, et al. Refining the treatment of follicular lymphoma. Leuk Lymphoma 2008; 49Suppl. 1: 18–26PubMedCrossRefGoogle Scholar
  56. 56.
    Evens AM, Cilley J, Ortiz T, et al. G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. Br J Haematol 2007 Jun; 137(6): 545–52PubMedCrossRefGoogle Scholar
  57. 57.
    Martin WG, Ristow KM, Habermann TM, et al. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin’s lymphoma. J Clin Oncol 2005 Oct 20; 23(30): 7614–20PubMedCrossRefGoogle Scholar
  58. 58.
    Horning SJ, Hoppe RT, Breslin S, et al. Stanford V and radiotherapy for locally extensive and advanced Hodgkin’s disease: mature results of a prospective clinical trial. J Clin Oncol 2002 Feb 1; 20(3): 630–7PubMedCrossRefGoogle Scholar
  59. 59.
    Hoskin P. Randomised comparison of the Stanford V regimen and ABVD in the treatment of advanced Hodgkin lymphoma: results from a UK NCRI lymphoma group study, ISRCTN 6414244. J Clin Oncol. In pressGoogle Scholar
  60. 60.
    Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 2005 Jun; 23(18): 4117–26PubMedCrossRefGoogle Scholar
  61. 61.
    Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclo-phosphamide, doxorubicin, vincristine, and prednisolone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005 Dec; 106(12): 3725–32PubMedCrossRefGoogle Scholar
  62. 62.
    Witzig TE, Vukov AM, Habermann TM, et al. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin’s lymphoma: a phase II trial in the North Central Cancer Treatment Group. J Clin Oncol 2005 Feb; 23(6): 1103–8PubMedCrossRefGoogle Scholar
  63. 63.
    Cattaneo C, Spedini P, Casari S, et al. Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments. Leuk Lymphoma 2006 Jun; 47(6): 1013–7PubMedCrossRefGoogle Scholar
  64. 64.
    Marchi E, Alinari L, Tani M, et al. Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients. Cancer 2005 Dec; 104(11): 2437–41PubMedCrossRefGoogle Scholar
  65. 65.
    Tsimberidou AM, Younes A, Romaguera J, et al. Immuno-suppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen. Cancer 2005 Jul; 104(2): 345–53PubMedCrossRefGoogle Scholar
  66. 66.
    Larson RA, Dodge RK, Linker CA, et al. A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood 1998 Sep; 92(5): 1556–64PubMedGoogle Scholar
  67. 67.
    Linker C, Damon L, Ries C, et al. Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia. J Clin Oncol 2002 May; 20(10): 2464–71PubMedCrossRefGoogle Scholar
  68. 68.
    Rowe JM, Buck G, Burnett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood 2005 Dec; 106(12): 3760–7PubMedCrossRefGoogle Scholar
  69. 69.
    Takeuchi J, Kyo T, Naito K, et al. Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study. Leukemia 2002 Jul; 16(7): 1259–66PubMedCrossRefGoogle Scholar
  70. 70.
    Vaccher E, Spina M, Talamini R, et al. Improvement of systemic human immunodeficiency virus-related non-Hodgkin lymphoma outcome in the era of highly active antiretroviral therapy. Clin Infect Dis 2003 Dec; 37(11): 1556–64PubMedCrossRefGoogle Scholar
  71. 71.
    Lim ST, Karim R, Nathwani BN, et al. AIDS-related Burkitt’s lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. J Clin Oncol 2005 Jul; 23(19): 4430–8PubMedCrossRefGoogle Scholar
  72. 72.
    Mounier N, Spina M, Gabarre J, et al. AIDS-related non-Hodgkin’s lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy. Blood 2006 May; 107(10): 3832–40PubMedCrossRefGoogle Scholar
  73. 73.
    Remick SC, Sedransk N, Haase RF, et al. Oral combination chemotherapy in conjunction with filgrastim (G-CSF) in the treatment of AIDS-related non-Hodgkin’s lymphoma: evaluation of the role of G-CSF; quality-of-life analysis and long-term follow-up. Am J Hematol 2001 Mar; 66(3): 178–88PubMedCrossRefGoogle Scholar
  74. 74.
    Sawka CA, Shepherd FA, Franssen E, et al. A prospective, non-randomised phase 1-2 trial of VACOP-B with filgrastim support for HIV-related non-Hodgkin’s lymphoma. Biotech Ann Rev 2005; 11: 381–9CrossRefGoogle Scholar
  75. 75.
    Navarro JT, Ribera JM, Oriol A, et al. International prognostic index is the best prognostic factor for survival in patients with AIDS-related non-Hodgkin’s lymphoma treated with CHOP: a multivariate study of 46 patients. Haematologica 1998 Jun; 83(6): 508–13PubMedGoogle Scholar
  76. 76.
    Boué F, Gabarre J, Gisselbrecht C, et al. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin’s lymphoma. J Clin Oncol 2006 Sep; 24(25): 4123–8PubMedCrossRefGoogle Scholar
  77. 77.
    Spina M, Gabarre J, Rossi G, et al. Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection. Blood 2002 Sep; 100(6): 1984–8PubMedCrossRefGoogle Scholar
  78. 78.
    Velasquez WS, McLaughlin P, Tucker S, et al. ESHAP — an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 1994 Jun; 12(6): 1169–76PubMedGoogle Scholar
  79. 79.
    Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988 Jan; 71(1): 117–22PubMedGoogle Scholar
  80. 80.
    Pfreundschuh MG, Rueffer U, Lathan B, et al. Dexa-BEAM in patients with Hodgkin’s disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin’s Disease Study Group. J Clin Oncol 1994 Mar; 12(3): 580–6PubMedGoogle Scholar
  81. 81.
    Colwill R, Crump M, Couture F, et al. Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin’s disease before intensive therapy and autologous bone marrow transplantation. J Clin Oncol 1995 Feb; 13(2): 396–402PubMedGoogle Scholar
  82. 82.
    Vose J, Sneller V. Outpatient regimen rituximab plus ifosfamide, carboplatin and etoposide (R-ICE) for relapsed non-Hodgkin’s lymphoma. Ann Oncol 2003; 14Suppl. 1: i1 17–20Google Scholar
  83. 83.
    Crawley CR, Foran JM, Gupta RK, et al. A phase II study to evaluate the combination of fludarabine, mitoxantrone and dexamethasone (FMD) in patients with follicular lymphoma. Ann Oncol 2000 Jul; 11(7): 861–5PubMedCrossRefGoogle Scholar
  84. 84.
    Wilder DD, Ogden JL, Jain VK. A multicenter trial of infusional etoposide, doxorubicin, and vincristine with cyclophosphamide and prednisone (EPOCH) in patients with relapsed non-Hodgkin’s lymphoma. Clin Lymphoma 2001 Mar; 1(4): 285–92PubMedCrossRefGoogle Scholar
  85. 85.
    Crump M, Baetz T, Couban S, et al. Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). Cancer 2004 Oct; 101(8): 1835–42PubMedCrossRefGoogle Scholar
  86. 86.
    Morschhauser F, Depil S, Jourdan E, et al. Phase II study of gemcitabine-dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma. Ann Oncol 2007 Feb; 18(2): 370–5PubMedCrossRefGoogle Scholar
  87. 87.
    Ng M, Waters J, Cunningham D, et al. Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma. Br J Cancer 2005 Apr; 92(8): 1352–7PubMedCrossRefGoogle Scholar
  88. 88.
    Pro B, Fayad L, McLaughlin P, et al. Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relapsed aggressive non-Hodgkin’s lymphoma. Leuk Lymphoma 2006 Mar; 47(3): 481–5PubMedCrossRefGoogle Scholar
  89. 89.
    Zinzani PL, Baliva G, Magagnoli M, et al. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol 2000 Jul; 18(13): 2603–6PubMedGoogle Scholar
  90. 90.
    Dumontet C, Morschhauser F, Solal-Celigny P, et al. Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin’s lymphoma. Br J Haematol 2001 Jun; 113(3): 772–8PubMedCrossRefGoogle Scholar
  91. 91.
    Venkatesh H, Di Bella N, Flynn TP, et al. Results of a phase II multicenter trial of single-agent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin’s lymphoma. Clin Lymphoma 2004 Sep; 5(2): 110–15PubMedCrossRefGoogle Scholar
  92. 92.
    Walewski J, Kraszewska E, Mioduszewska O, et al. Rituximab (Mabthera, Rituxan) in patients with recurrent indolent lymphoma: evaluation of safety and efficacy in a multicenter study. Med Oncol 2001; 18(2): 141–8PubMedCrossRefGoogle Scholar
  93. 93.
    Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 2002 May; 20(10): 2453–63PubMedCrossRefGoogle Scholar
  94. 94.
    Linch DC, Milligan DW, Winfield DA, et al. G-CSF after peripheral blood stem cell transplantation in lymphoma patients significantly accelerated neutrophil recovery and shortened time in hospital: results of a randomized BNLI trial. Br J Haematol 1997 Dec; 99(4): 933–8PubMedCrossRefGoogle Scholar
  95. 95.
    Hornedo J, Sola C, Solano C, et al. The role of granulocyte colony-stimulating factor (G-CSF) in the post-transplant period. Bone Marrow Transplant 2002 May; 29(9): 737–43PubMedCrossRefGoogle Scholar
  96. 96.
    Schmitz N, Ljungman P, Cordonnier C, et al. Lenograstim after autologous peripheral blood progenitor cell transplantation: results of a double-blind, randomized trial. Bone Marrow Transplant 2004 Dec; 34(11): 955–62PubMedCrossRefGoogle Scholar
  97. 97.
    Valteau-Couanet D, Faucher C, Aupérin A, et al. Cost effectiveness of day 5 G-CSF (lenograstim) administration after PBSC transplantation: results of a SFGM-TC randomised trial. Bone Marrow Transplant 2005 Sep; 36(6): 547–52PubMedCrossRefGoogle Scholar
  98. 98.
    Faber E, Pytlík R, Slabý J, et al. Individually determined dosing of filgrastim after autologous peripheral stem cell transplantation in patients with malignant lymphoma: results of a prospective multicentre controlled trial. Eur J Haematol 2006 Dec; 77(6): 493–500PubMedCrossRefGoogle Scholar
  99. 99.
    Dekker A, Bulley S, Beyene J, et al. Meta-analysis of randomized controlled trials of prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor after autologous and allogeneic stem cell transplantation. J Clin Oncol 2006 Nov; 24(33): 5207–15PubMedCrossRefGoogle Scholar
  100. 100.
    Meyer RM, Hryniuk WM, Goodyear MD. The role of dose intensity in determining outcome in intermediate-grade non-Hodgkin’s lymphoma. J Clin Oncol 1991 Feb; 9(2): 339–47PubMedGoogle Scholar
  101. 101.
    Lepage E, Gisselbrecht C, Haioun C, et al. Prognostic significance of received relative dose intensity in non-Hodgkin’s lymphoma patients: application to LNH-87 protocol. Ann Oncol 1993 Sep; 4(8): 651–6PubMedGoogle Scholar
  102. 102.
    Landgren O, Algernon C, Axdorph U, et al. Hodgkin’s lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis. Haematologica 2003 Apr; 88(4): 438–44PubMedGoogle Scholar
  103. 103.
    Lyman GH, Dale DC, Friedberg J, et al. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin’s lymphoma: a nationwide study. J Clin Oncol 2004 Nov; 22(21): 4302–11PubMedCrossRefGoogle Scholar
  104. 104.
    Lee KW, Kim DY, Yun T, et al. Doxorubicin-based chemotherapy for diffuse large B-cell lymphoma in elderly patients: comparison of treatment outcomes between young and elderly patients and the significance of doxorubicin dosage. Cancer 2003 Dec 15; 98(12): 2651–6PubMedCrossRefGoogle Scholar
  105. 105.
    Kwak LW, Halpern J, Olshen RA, et al. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol 1990 Jun; 8(6): 963–77PubMedGoogle Scholar
  106. 106.
    Bosly A, Bron D, Van Hoof A, et al. Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. Ann Hematol 2007 Oct 20; 87(4): 277–83PubMedCrossRefGoogle Scholar
  107. 107.
    Pettengell R, Schwenkglenks M, Bosly A. Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy. Ann Hematol 2008 May; 87(5): 429–30PubMedCrossRefGoogle Scholar
  108. 108.
    Hackshaw A, Sweetenham J, Knight A. Are prophylactic haematopoietic growth factors of value in the management of patients with aggressive non-Hodgkin’s lymphoma? Br J Cancer 2004 Apr; 90(7): 1302–5PubMedCrossRefGoogle Scholar
  109. 109.
    Bohlius J, Reiser M, Schwarzer G, et al. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev2004;(3):CD003189Google Scholar
  110. 110.
    Gerhartz HH, Engelhard M, Meusers P, et al. Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin’s lymphomas. Blood 1993 Oct; 82(8): 2329–39PubMedGoogle Scholar
  111. 111.
    Fridrik MA, Greil R, Hausmaninger H, et al. Randomized open label phase III trial of CEOP/IMVP-dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-dexa alternating chemotherapy for aggressive non-Hodgkin’s lymphoma (NHL): a multicenter trial by the Austrian Working Group For Medical Tumor Therapy. Ann Hematol 1997 Oct; 75(4): 135–40PubMedCrossRefGoogle Scholar
  112. 112.
    Souêtre E, Qing W. Economic analysis of lenograstim in the correction of neutropenia following chemotherapy for non-Hodgkin’s lymphoma. Pharmacoeconomics 1994; 6Suppl. 2: 36–43PubMedCrossRefGoogle Scholar
  113. 113.
    Kuderer NM, Dale DC, Crawford J, et al. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 2007 Jul 20; 25(21): 3158–67PubMedCrossRefGoogle Scholar
  114. 114.
    Sung L, Nathan PC, Alibhai SM, et al. Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. Ann Intern Med 2007 Sep 18; 147(6): 400–11PubMedGoogle Scholar
  115. 115.
    Bohlius J, Herbst C, Reiser M, et al. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev2008;(4):CD003189Google Scholar
  116. 116.
    Lyman GH, Dale DC, Wolff D, et al. Standard versus dose-intensified chemotherapy with granulocyte colony-stimulating factor for malignant lymphoma: evaluation of risk for acute myeloid leukemia or myelodysplastic syndrome [abstract]. Blood (ASH Annual Meeting Abstracts) 2008; 112(11): 2390Google Scholar
  117. 117.
    Lyman G, Kuderer N, Crawford J, et al. Impact of pegfilgrastim on early all-cause mortality in patients receiving cancer chemotherapy [abstract]. J Clin Oncol 2008; 26 (May 20 Suppl.): 6552Google Scholar
  118. 118.
    Engel C, Loeffler M, Schmitz S, et al. Acute hematologic toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin’s disease. Ann Oncol 2000 Sep; 11(9): 1105–14PubMedCrossRefGoogle Scholar
  119. 119.
    Rigacci L, Nassi L, Alterini R, et al. Dose-dense CHOP plus rituximab (R-CHOP14) for the treatment of elderly patients with high-risk diffuse large B cell lymphoma: a pilot study. Acta Haematol 2006; 115(1-2): 22–7PubMedCrossRefGoogle Scholar
  120. 120.
    Vose JM, Crump M, Lazarus H, et al. Randomized, multi-center, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol 2003 Feb; 21(3): 514–19PubMedCrossRefGoogle Scholar
  121. 121.
    Kewalramani T, Zelenetz AD, Nimer SD, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004 May 15; 103(10): 3684–8PubMedCrossRefGoogle Scholar
  122. 122.
    Martin A, Conde E, Arnan M, et al. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study. Haematologica 2008 Dec; 93(12): 1829–36PubMedCrossRefGoogle Scholar
  123. 123.
    Gisselbrecht C, Schmitz N, Mounier N, et al. R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by stem cell transplantation and maintenance treatment with rituximab or not: first interim analysis on 200 patients. CORAL study [abstract]. Blood (ASH Annual Meeting Abstracts) 2007; 110(11): 517Google Scholar
  124. 124.
    Dearden CE, Matutes E. Alemtuzumab in T-cell lympho-proliferative disorders. Best Pract Res 2006; 19(4): 795–810Google Scholar
  125. 125.
    Fanale MA, Younes A. Monoclonal antibodies in the treatment of non-Hodgkin’s lymphoma. Drugs 2007; 67(3): 333–50PubMedCrossRefGoogle Scholar
  126. 126.
    Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20 + B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008 Feb; 9(2): 105–16PubMedCrossRefGoogle Scholar
  127. 127.
    Poeschel V, Nickelsen M, Hanel M, et al. Dose-dense rituximab in combination with biweekly CHOP-14 for elderly patients with diffuse large B-cell lymphoma (DLBCL): results of a phase-I/II and pharmacokinetic study of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood (ASH Annual Meeting Abstracts) 2006; 108(11): 2738Google Scholar
  128. 128.
    Gallamini A, Zaja F, Patti C, et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 2007 Oct 1; 110(7): 2316–23PubMedCrossRefGoogle Scholar
  129. 129.
    Kim JG, Sohn SK, Chae YS, et al. Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study. Cancer Chemother Pharmacol 2007 Jun; 60(1): 129–34PubMedCrossRefGoogle Scholar
  130. 130.
    Weidmann E, Hess G, Krause SW, et al. A phase II immunochemotherapy study with alemtuzumab, fludar-abine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas [abstract]. Blood (ASH Annual Meeting Abstracts) 2006; 108(11): 2721Google Scholar
  131. 131.
    Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002 Mar 15; 34(6): 730–51PubMedCrossRefGoogle Scholar
  132. 132.
    Kolstad A, Holte H, Fossa A, et al. Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen. Haematologica 2007 Jan; 92(1): 139–40PubMedCrossRefGoogle Scholar
  133. 133.
    Czuczman MS, Koryzna A, Mohr A, et al. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol 2005 Feb 1; 23(4): 694–704PubMedCrossRefGoogle Scholar
  134. 134.
    Visani G, Mele A, Guiducci B, et al. An observational study of once weekly intravenous ganciclovir as CMV prophylaxis in heavily pre-treated chronic lymphocytic leukemia patients receiving subcutaneous alemtuzumab. Leuk Lymphoma 2006 Dec; 47(12): 2542–6PubMedCrossRefGoogle Scholar
  135. 135.
    National Comprehensive Cancer Network. Fever and neutropenia. Practice Guidelines in Oncology. Prevention and treatment of cancer-related infections, v1, 2008 [online]. Available from URL: http://www.nccn.org [Accessed 2009 Jun 30]Google Scholar
  136. 136.
    Mansharamani NG, Balachandran D, Vernovsky I, et al. Peripheral blood CD4+ T-lymphocyte counts during Pneumocystis carinii pneumonia in immunocompromised patients without HIV infection. Chest 2000; 118: 712–20PubMedCrossRefGoogle Scholar
  137. 137.
    Avilés A, Guzmán R, Garcia EL, et al. Results of a randomized trial of granulocyte colony-stimulating factor in patients with infection and severe granulocytopenia. Anticancer Drugs 1996 Jun; 7(4): 392–7PubMedCrossRefGoogle Scholar
  138. 138.
    Ravaud A, Chevreau C, Cany L, et al. Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial. J Clin Oncol 1998 Sep; 16(9): 2930–6PubMedGoogle Scholar
  139. 139.
    Clark OA, Lyman GH, Castro AA, et al. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol 2005 Jun; 23(18): 4198–214PubMedCrossRefGoogle Scholar
  140. 140.
    Pinto L, Liu Z, Doan Q, et al. Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. Curr Med Res Opin 2007 Sep; 23(9): 2283–95PubMedCrossRefGoogle Scholar
  141. 141.
    Younes A, Fayad L, Romaguera J, et al. Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma. Eur J Cancer 2006 Nov; 42(17): 2976–81PubMedCrossRefGoogle Scholar
  142. 142.
    Pettengell R, Skacel T, Aapro M, et al. Pegfilgrastim provides effective primary prophylaxis against febrile neutropenia in patients with NHL undergoing chemotherapy: initial results from an integrated analysis. The Neulasta versus Current neutropenia management Practice (NeuCuP) project [abstract]. Blood 2006 Aug; 108(4): 1150Google Scholar
  143. 143.
    Balducci L, Al-Halawani H, Charu V, et al. Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim. Oncologist 2007 Dec; 12(12): 1416–24PubMedCrossRefGoogle Scholar
  144. 144.
    Pettengell R, Booth P, Malin J, et al. Primary prophylaxis with pegfilgrastim was more cost-effective than filgrastim in patients with non-Hodgkin’s lymphoma receiving CHOP-21 in the UK [abstract 0602]. Haematologica 2007; 92Suppl. 2: 224Google Scholar

Copyright information

© Adis Data Information BV 2009

Authors and Affiliations

  • Ruth Pettengell
    • 1
  • Matti Aapro
    • 2
  • Ercole Brusamolino
    • 3
  • Dolores Caballero
    • 4
  • Bertrand Coiffier
    • 5
  • Michael Pfreundschuh
    • 6
  • Marek Trneny
    • 7
  • Jan Walewski
    • 8
  1. 1.Department of HaematologySt George’s University of LondonLondonUK
  2. 2.Doyen IMO Clinique de GenolierGenolierSwitzerland
  3. 3.Clinica Ematologica, Fondazione Policlinico San Matteo IRCCSUniversità di PaviaPaviaItaly
  4. 4.Haematology DepartmentUniversity HospitalSalamancaSpain
  5. 5.HaematologyCentral Hospital Lyon-SudLyonFrance
  6. 6.Medizinische Klinik IUniversität des SaarlandesHomburgGermany
  7. 7.1st Department of MedicineCharles University in Prague, First Faculty of Medicine and General Teaching HospitalPrahaCzech Republic
  8. 8.The Maria Sklodowska-Curie Memorial Institute and Cancer CentreWarsawPoland

Personalised recommendations